In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 480-492

  Fernandez, C S ^a   Jegaskanda, S ^a   Godfrey, D I ^a   Kent, S J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

galactosylceramide; GalCer; Activation; Influenza virus; Macaques; NKT cells; SIV infection

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNOTHERAPY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MACACA; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; STIMULATION; VACCINATION; VIRUS IMMUNITY;

Α-GALACTOSYLCERAMIDE; Α-GALCER; ACTIVATION; INFLUENZA VIRUS; MACAQUES; NKT CELLS; SIV INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; GALACTOSYLCERAMIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MACACA NEMESTRINA; MONKEY DISEASES; NATURAL KILLER T-CELLS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84881529153     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12132     Document Type: Article

References (68)

1. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011; 11:131-142.
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
3. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med 1997; 186:109-120.
4. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-237.
5. Eger KA, Sundrud MS, Motsinger AA, Tseng M, Van Kaer L, Unutmaz D. Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions. PLoS ONE 2006; 1:e50.
6. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114:1379-1388.
7. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010; 11:197-206.
8. Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol 2008; 127:1-6.
9. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002; 195:869-879.
10. van der Vliet HJ, von Blomberg BM, Hazenberg MD etal. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol 2002; 168:1490-1495.
11. Motsinger A, Azimzadeh A, Stanic AK etal. Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. J Virol 2003; 77:8153-8158.
12. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ. Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol 2009; 83:1617-1624.
13. Sandberg JK, Fast NM, Palacios EH etal. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol 2002; 76:7528-7534.
14. Uchida T, Horiguchi S, Tanaka Y etal. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57:337-345.
15. Kunii N, Horiguchi S, Motohashi S etal. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009; 100:1092-1098.
16. Yamasaki K, Horiguchi S, Kurosaki M etal. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138:255-265.
17. Giaccone G, Punt CJ, Ando Y etal. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8:3702-3709.
18. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12:239-252.
19. Chang DH, Osman K, Connolly J etal. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201:1503-1517.
20. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3:867-874.
21. Schneiders FL, Scheper RJ, von Blomberg BM etal. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011; 140:130-141.
22. Emoto M, Emoto Y, Yoshizawa I etal. Alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver. Eur J Immunol 2010; 40:1328-1341.
23. Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during viral infection. PLoS Pathog 2012; 8:e1002838.
24. Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011; 53:263-270.
25. Hong S, Wilson MT, Serizawa I etal. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052-1056.
26. Wu L, Van Kaer L. Natural killer T cells and autoimmune disease. Curr Mol Med 2009; 9:4-14.
27. De Santo C, Salio M, Masri SH etal. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008; 118:4036-4048.
28. Exley MA. Editorial: NKT get the 'flu: NKT cells as (mostly) good guys in influenza; monocytic cells as double agents. J Leukoc Biol 2012; 91:349-352.
29. Guillonneau C, Mintern JD, Hubert FX etal. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009; 106:3330-3335.
30. Galli G, Pittoni P, Tonti E etal. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 2007; 104:3984-3989.
31. Youn HJ, Ko SY, Lee KA etal. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007; 25:5189-5198.
32. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, Brossay L. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS ONE 2012; 7:e37991.
33. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:921-930.
34. Huang Y, Chen A, Li X etal. DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine 2008; 26:1807-1816.
35. Dondji B, Deak E, Goldsmith-Pestana K etal. Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 2008; 38:706-719.
36. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009; 182:6435-6443.
37. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009; 9:28-38.
38. Chea S, Dale CJ, De Rose R, Ramshaw IA, Kent SJ. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol 2005; 79:3748-3757.
39. De Rose R, Fernandez CS, Smith MZ etal. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 2008; 4:e1000055.
40. Fernandez CS, Reece JC, Saepuloh U etal. Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics 2011; 63:511-521.
41. Fernandez CS, Cameron G, Godfrey DI, Kent SJ. Ex-vivo alpha-galactosylceramide activation of NKT cells in humans and macaques. J Immunol Methods 2012; 382:150-159.
42. Jegaskanda S, Reece JC, De Rose R etal. Comparison of influenza and SIV specific CD8 T cell responses in macaques. PLoS ONE 2012; 7:e32431.
43. Sexton A, De Rose R, Reece JC etal. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009; 83:7619-7628.
44. Motohashi S, Ishikawa A, Ishikawa E etal. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12:6079-6086.
45. Motohashi S, Nagato K, Kunii N etal. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182:2492-2501.
46. Nieda M, Okai M, Tazbirkova A etal. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103:383-389.
47. Ishikawa A, Motohashi S, Ishikawa E etal. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11:1910-1917.
48. Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells. Clin Cancer Res 2011; 17:5140-5151.
49. Gansuvd B, Goodwin J, Asiedu CK etal. Invariant natural killer T cells from rhesus macaque spleen and peripheral blood are phenotypically and functionally distinct populations. J Med Primatol 2008; 37:1-11.
50. Rout N, Else JG, Yue S, Connole M, Exley MA, Kaur A. Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infection. PLoS ONE 2010; 5:e9787.
51. Uldrich AP, Crowe NY, Kyparissoudis K etal. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005; 175:3092-3101.
52. Crowe NY, Uldrich AP, Kyparissoudis K etal. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171:4020-4027.
53. Wilson MT, Johansson C, Olivares-Villagomez D etal. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100:10913-10918.
54. Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. HIV/AIDS: in search of an animal model. Trends Biotechnol 2007; 25:333-337.
55. Hatziioannou T, Ambrose Z, Chung NP etal. A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 2009; 106:4425-4429.
56. Lackner AA, Veazey RS. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 2007; 58:461-476.
57. Richt JA, Rockx B, Ma W etal. Recently emerged swine influenza A virus (H2N3) causes severe pneumonia in Cynomolgus macaques. PLoS ONE 2012; 7:e39990.
58. Woltman AM, Ter Borg MJ, Binda RS etal. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 2009; 14:809-818.
59. Harada M, Seino K, Wakao H etal. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int Immunol 2004; 16:241-247.
60. Subleski JJ, Hall VL, Wolfe TB etal. TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells. J Immunol 2011; 186:838-847.
61. Parekh VV, Wilson MT, Olivares-Villagomez D etal. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115:2572-2583.
62. Stetson DB, Mohrs M, Reinhardt RL etal. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003; 198:1069-1076.
63. Matsuda JL, Gapin L, Baron JL etal. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003; 100:8395-8400.
64. Parekh VV, Lalani S, Kim S etal. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009; 182:2816-2826.
65. Chang WS, Kim JY, Kim YJ etal. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008; 181:6707-6710.
66. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M etal. alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000; 97:8461-8466.
67. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC etal. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002; 195:617-624.
68. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. Alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005; 175:3309-3317.